NCT03032614 is a Phase 2 clinical trial of Carboplatin in Breast Cancer Stage IV, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT03032614?

NCT03032614 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT03032614?

Interventions in NCT03032614: Carboplatin, Eribulin, Veliparib.

What condition does NCT03032614 study?

NCT03032614 studies Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation.

Is NCT03032614 still recruiting?

NCT03032614 is currently withdrawn. Last updated 10 October 2017.

Last reviewed 2017-10-10 · How we verify

NCT03032614

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Withdrawn Phase 2 Last updated 10 October 2017

What this trial tests

Phase 2 trial testing Carboplatin in Breast Cancer Stage IV. Withdrawn.

Timeline

30 September 2017

Primary endpoint
31 March 2019

30 April 2020

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	30 September 2017
Primary completion	31 March 2019
Estimated completion	30 April 2020

Drugs / interventions tested

Carboplatin (Carboplatin) — full drug profile →
Eribulin (ERIBULIN) — full drug profile →
Veliparib — full drug profile →

Conditions studied

Breast Cancer Stage IV — all drugs for Breast Cancer Stage IV →
Ovarian Cancer — all drugs for Ovarian Cancer →
BRCA1 Mutation — all drugs for BRCA1 Mutation →
BRCA2 Mutation — all drugs for BRCA2 Mutation →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

18 and older, female only, with Breast Cancer Stage IV or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Marine Sponge Natural Products with Anticancer Potential: An Updated Review.
Calcabrini C, Catanzaro E, Bishayee A, Turrini E, et al · · 2017 · cited 91× · PMID 29027954 · DOI 10.3390/md15100310

Verify or expand the search:

Other trials of Carboplatin

Trials testing the same drug.

NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting

Other recruiting trials for Breast Cancer Stage IV

Currently open trials in the same condition.

NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07371585 — Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management · Phase 2 · recruiting
NCT06830382 — HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC · recruiting
NCT06889688 — Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast · Phase 3 · active not recruiting
NCT06678269 — A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer · Phase 1 · recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03032614 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 10 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03032614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing